Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
7 June 2024
| m 17:15 | TATA box gene transcriptions diffhist +64 Marshallsumter talk contribs (→Human genes) | ||||
6 June 2024
| m 05:10 | A1BG response element gene transcriptions diffhist +24 Marshallsumter talk contribs (→Response element testing) | ||||
5 June 2024
|
|
m 06:42 | A1BG response element gene transcriptions 5 changes history +63 [Marshallsumter (5×)] | |||
| m |
|
06:42 (cur | prev) +7 Marshallsumter talk contribs (→Response element testing) | |||
| m |
|
05:02 (cur | prev) +24 Marshallsumter talk contribs | |||
| m |
|
04:58 (cur | prev) +1 Marshallsumter talk contribs (→Response element testing) | |||
| m |
|
02:01 (cur | prev) +33 Marshallsumter talk contribs (→Response element testing) | |||
| m |
|
00:50 (cur | prev) −2 Marshallsumter talk contribs (→Response element testing) | |||
2 June 2024
| 23:19 | User:Rithish Nimmagadda diffhist +14 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 23:19 | Iptacopa diffhist +11,398 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=iptacopa |aOrAn=a |drugClass=complement factor B inhibitor. |indicationType=treatment |indication=adults with paroxysmal nocturnal hemoglobinuria (PNH). |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions in adults with PNH (incidence ≥10%) were headache, nasopharyngitis, diarrhea, abdominal pain, bacterial infection, viral infection, nausea, and rash. |blackBoxWarningTitle=Serious Infecti...") | ||||
| 03:28 | WINREVAIR diffhist +581 Kosar Doraghi talk contribs | ||||
|
|
02:54 | (Upload log) [Kosar Doraghi (9×)] | |||
|
|
02:54 Kosar Doraghi talk contribs uploaded File:IMG 1235.jpeg | ||||
|
|
02:53 Kosar Doraghi talk contribs uploaded File:IMG 1234.jpeg | ||||
|
|
02:52 Kosar Doraghi talk contribs uploaded File:IMG 1231.jpeg | ||||
|
|
02:51 Kosar Doraghi talk contribs uploaded File:IMG 1232.jpeg | ||||
|
|
02:49 Kosar Doraghi talk contribs uploaded File:IMG 1230.jpeg | ||||
|
|
02:49 Kosar Doraghi talk contribs uploaded File:IMG 1227.jpeg | ||||
|
|
02:48 Kosar Doraghi talk contribs uploaded File:IMG 1236.jpeg | ||||
|
|
02:46 Kosar Doraghi talk contribs uploaded File:IMG 1237.jpeg | ||||
|
|
02:41 Kosar Doraghi talk contribs uploaded File:IMG 1226.jpeg | ||||
1 June 2024
| 03:21 | Template:KDRG diffhist +15 Kosar Doraghi talk contribs | ||||
| N 03:20 | WINREVAIR diffhist +16,566 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sotatercept-csrk |aOrAn=an |drugClass=activin signaling inhibitor |indicationType=treatment |indication=adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events |hasBlackBoxWarning=Yes |adverseReactions=headache, epistaxis, rash, telangiect...") | ||||
31 May 2024
|
|
m 23:35 | Non-degenerate nucleotides per response element 2 changes history +1 [Marshallsumter (2×)] | |||
| m |
|
23:35 (cur | prev) 0 Marshallsumter talk contribs (→Averages per Orders) | |||
| m |
|
23:18 (cur | prev) +1 Marshallsumter talk contribs (→Averages per Orders) | |||
30 May 2024
|
|
m 23:53 | Non-degenerate nucleotides per response element 2 changes history −52 [Marshallsumter (2×)] | |||
| m |
|
23:53 (cur | prev) +2 Marshallsumter talk contribs (→Averages per Orders) | |||
| m |
|
06:03 (cur | prev) −54 Marshallsumter talk contribs (→Tabulation of counts) | |||
28 May 2024
| m 07:35 | Non-degenerate nucleotides per response element diffhist 0 Marshallsumter talk contribs (→Tabulation of counts) | ||||
27 May 2024
|
|
N 23:47 | Template:JR 2 changes history +44 [Jonathan Reyes (2×)] | |||
|
|
23:47 (cur | prev) −25 Jonathan Reyes talk contribs | ||||
| N |
|
22:59 (cur | prev) +69 Jonathan Reyes talk contribs (Created page with "Jonathan Reyes, M.D.[jona3098reyes@gmail.com]") | |||
| N 23:42 | Evinacumab-dgnb diffhist +627 Jonathan Reyes talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{JR}} |genericName=evinacumab-dgnb |aOrAn=an |drugClass=angiopoietin-like 3 (ANGPTL3) inhibitor |indicationType=treatment |indication=Evanicumab-dgnb is an angiopoietin-like 3 (ANGPTL3) inhibitor that is FDA approved for the treatment of an adjunct to other low-density lipoproteincholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholestero...") | ||||
26 May 2024
| m 20:05 | Non-degenerate nucleotides per response element diffhist −50 Marshallsumter talk contribs (→Tabulation of counts) | ||||
25 May 2024
| m 19:41 | Non-degenerate nucleotides per response element diffhist 0 Marshallsumter talk contribs (→Averages per Orders) | ||||